

Date: August 13, 2024

To
The Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Ref: Scrip code: 532669

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that, the meeting of the Board of Directors of the Company held on Tuesday, August 13, 2024, commenced at 8.30 P.M and concluded at 09.20 P.M.

The Board inter-alia considered and approved the following:

- 1. Approved the unaudited standalone financial results of the Company for the quarter ended June 30, 2024. (enclosed herewith)
- 2. Took note of the Limited Review Report issued by M/s. Darapaneni & Co., Chartered Accountants, Statutory Auditors of the Company on the unaudited standalone financial results for the quarter ended June 30, 2024. (enclosed herewith)

You are requested to take the same on your record.

Thanking you

For Southern Online Bio Technologies Limited

Dr Devaiah Pagidipati Managing Director

Encl: A/a.



M/s. Southern Online Biotechnologies Limited Un – Audited Financial Results For The Quarter Ended 30th June 2024

				Quarter Ended	Rs. Lakhs Year Ended			
	Particulars		30.06.2024 31.03.2024 30.06.2023			30.06.2024 31.03.2024		
			Unaudited	Audited	Unaudited	Unaudited	Audited	
ı	Reven	ue from operations						
	Sale o	f goods/Income from operations	4,644.98	1,599.92	1,162.89	4,644.98	6,732.85	
	Other	operating revenues						
	Total r	evenue from operations	4,644.98	1,599.92	1,162.89	4,644.98	6,732.85	
П	Other	income	15.64	18.16	4.81	15.64	45.71	
III	Total income (I+II)		4,660.62	1,618.08	1,167.70	4,660.62	6,778.56	
	Total	meone (m)	4,000.02	1,010.00	1,107.70	4,000.02	0,770.30	
IV	Expenses							
	a)	Cost of materials consumed	3,577.39	1,185.50	1,787.94	3,577.39	6,061.87	
	b)	Purchases of stock- in-trade	-	_,	_,,	3,011100	-,	
	5,	Changes in inventories of						
	c)	finished goods and work in progress	719.22	149.85	(833.15)	719.22	(367.72)	
	d)	Employee benefits expenses	68.44	95.14	85.41	68.44	369.14	
	e)	Finance costs	73.76	88.38	150.29	73.76	570.89	
	f)	Depreciation and amortisation expense	93.58	93.34	75.23	93.58	357.43	
	g)	Other expenses	181.89	136.55	127.62	181.89	511.25	
	Total expenses		4,714.27	1,748.76	1,393.34	4,714.27	7,502.86	
	Total	expenses	7,717.27	1,740.70	1,333.34	7,7 17.27	7,302.00	
V		/(loss) before Exceptional nd tax (III-IV)	(53.65)	(130.68)	(225.64)	(53.65)	(724.30)	
	Exceptional Item (Net of Taxes)							
VI	Profit/(loss) before Tax		(53.65)	(<mark>130</mark> .68)	(225.64)	(53.65)	(724.30)	
VII	Tax ex	rpenses:						
	a)	Current tax						
	b)	Deferred tax charge/(credit)	(13.50)	-	-	-(13.50)	-	
		Tax Expense	(13.50) (40.15)	-	-	(13.50)	-	
VIII		let Profit for the period (V-VI)		(130.68)	(225.64)	(40.15)	(724.30)	
IX	Other	comprehensive income (net of tax)						
	a)	(i) Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans	-	(0.99)		-	(1.19)	
	b)	Income tax relating to these items that will not be reclassified subsequently to profit or loss	-					
	Other comprehensive income / (loss) (net of tax)		-	(0.99)	-	-	(1.19)	
х	Total comprehensive income / (loss) (VII+VIII)		(40.15)	(131.67)	(225.64)	(40.15)	(725.49)	
ΧI		up Equity Share Capital ralue ₹ 10 each)	4,500.00	4,500.00	4,500.00	4,500.00	4,500.00	

CIN: L72900TG1998PLC030463



XII	Other Equity		(767.62)	(727.48)	(227.63)	(767.62)	(727.48)
XIII	Net Worth Paid-up debt Capital		3,732.38	3,772.52	4,272.37	3,732.38	3,772.52
XVII			-				
XVIII	Earnings per share (face value ₹ 10 each)		-				
	a)	Basic (₹)	(0.09)	(0.29)	(0.50)	(0.09)	(1.61)
	b)	Diluted (₹)	(0.09)	(0.29)	(0.50)	(0.09)	(1.61)
XIX	Ratios		-	-			-
	a)	Debt Equity Ratio	3.12	2.91	1.53	3.12	2.91
	b)	Debt Service Coverage Ratio	-	-	-	-	-
	c)	Interest Service Coverage Ratio	0.27	(0.26)	(0.50)	0.27	(0.27)
	d)	Current Ratio	1.49	1.99	1.33	1.49	1.99
	e)	Long term debt to working capital	6.90	5.63	9.41	6.90	5.63
	f)	Current liability ratio	0.23	0.15	0.24	0.23	0.15
	g)	Total debts to total assets	0.80	0.77	0.66	0.80	0.77
	h)	Bad debts to Account receivable ratio	-		-	-	
	i)	Debtors turnover	3.53	1.37	2.23	3.53	8.00
	j)	Inventory turnover	2.69	0.75	0.73	2.69	3.52
	k)	Operating margin (%)	0.10%	-4.01%	-6.89%	0.10%	-2.96%
	I)	Net profit margin (%)	-0.86%	0.00%	-19.40%	-0.86%	-10.76%

Notes:

- 1. The above Financial results have been reviewed by the audit committee, approved by the Board of Directors in its meeting held Aug 13, 2024 and reviewed by the Statutory auditors of the Company.
- 2. The Financial results of the Company have been prepared in accordance with Indian Accounting Standards (IND AS) notified under the Companies (Indian Accounting Standards) Rules 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.
- 3. Previous period's figure has been re-grouped/re-arranged wherever required in conformity with current period's presentation.

Your Faithfully

For Southern Online Bio Technologies Limited

Dr Devaiah Pagidipati Managing Director

Date: 13.08.2024 Place: Hyderabad

CIN: L72900TG1998PLC030463



M/s. Southern Online Biotechnologies Limited

Un – Audited Segmental Information for The Quarter Ended 30th June 2024

Rs. Lakhs

		Year Ended		
Particulars	30th Jun' 24	31 Mar'24	30 Jun'23	31 Mar'24
Segment Value of Sales and Services				
Internet Services	21.93	23.50	31.74	114.89
Bio Diesel	4,623.05	1,534.74	1,131.15	6,617.96
Revenue From Operations	4,644.98	1,558.24	1,162.89	6,732.85
Segment Results (EBITDA)				
Internet Services	(13.48)	(8.68)	(10.27)	(39.34)
Bio Diesel	127.17	59.71	5.35	243.35
Total Segment Profit before Interest, Tax,				
Exceptional item and Depreciation, Amortisation	113.69	51.03	(4.92)	204.01
and Depletion				
Segment Results (EBIT)				
Internet Services	(15.29)	(13.27)	(11.46)	(47.35)
Bio Diesel	19.76	(47.18)	(68.70)	(151.77)
Total Segment Profit before Interest and Tax and Exceptional item	4.47	(60.45)	(80.16)	(199.11)
(i) Finance Costs	73.76	88.38	150.29	570.89
(ii) Interest and other Income	15.64	18.16	4.81	45.71
Profit Before Exceptional Item and Tax Exceptional Item (Net of Taxes)	(53.65)	(130.67)	(225.64)	(724.29)
(iii) Exceptional Items (Net)				
Profit Before Tax	(53.65)	(130.67)	(225.64)	(724.29)
(i)Current Tax		-	-	-
(ii)Deferred Tax	(13.50)	-	-	-
Profit After Tax	(40.15)	(130.67)	(225.64)	(724.29)

Particulars		Year Ended		
Particulars	30th Jun' 24	31 Mar'24	30 Jun'23	31 Mar'24
Segmental Assets				
Internet Services	114.89	118.91	120.91	118.91
Bio Diesel	18,900.54	17,093.98	13 ,348.35	17,093.98
Total	19,015.43	17,212.89	13,469.27	17,212.89
Segmental Liabilities				
Internet Services	114.89	118.91	120.91	118.91
Bio Diesel	18,900.54	17,093.98	13,348.35	17,093.98
Total	19,015.43	17,212.89	13,469.27	17,212.89



DARAPANENI & Co., CHARTERED ACCOUNTANTS

Flat No 1A, Rama Apartments, Plot No.84, Srinagar Colony, Hyderabad - 500073.

Tel: 040-23735095, 23736487

E-mail: darapaneni1986@gmail.com

LIMITED REVIEW REPORT

Limited Review Report on Unaudited Quarterly Financial Results Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors of Southern Online Biotechnologies Limited

We have reviewed the accompanying statement of unaudited standalone financial results of M/s. SOUTHERN ONLINE BIOTECHNOLOGIES LIMITED, for the Quarter ended 30th June 2024 and year to date results for the period 01 April 2024 to 30th June 2024, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended) including relevant circulars issued by the SEBI from time to time

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: 13/08/2024 For Darapaneni & Co., **Chartered Accountants** FRN:000685S

SREE RAMA
CHANDRA MURTHY
CHEBROLU

Sree Rama Chandra Murthy Ch. Acco

Partner

M.no.233010

UDIN: 24233010BKASGN 1218

Hyderabad